Diplomat Pharmacy Inc (DPLO) Expected to Announce Quarterly Sales of $1.23 Billion

Wall Street analysts expect Diplomat Pharmacy Inc (NYSE:DPLO) to report sales of $1.23 billion for the current fiscal quarter, Zacks reports. Six analysts have made estimates for Diplomat Pharmacy’s earnings, with estimates ranging from $1.18 billion to $1.26 billion. Diplomat Pharmacy posted sales of $1.42 billion during the same quarter last year, which would indicate a negative year over year growth rate of 13.4%. The company is scheduled to report its next earnings report on Monday, August 5th.

On average, analysts expect that Diplomat Pharmacy will report full year sales of $4.89 billion for the current fiscal year, with estimates ranging from $4.82 billion to $4.95 billion. For the next financial year, analysts anticipate that the firm will post sales of $5.03 billion, with estimates ranging from $4.55 billion to $5.25 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that follow Diplomat Pharmacy.

Diplomat Pharmacy (NYSE:DPLO) last released its earnings results on Tuesday, May 7th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.26). Diplomat Pharmacy had a positive return on equity of 1.38% and a negative net margin of 5.85%. The company had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the prior year, the company posted ($0.01) earnings per share. The company’s revenue was down 6.4% on a year-over-year basis.

A number of research firms have recently commented on DPLO. Zacks Investment Research raised Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research note on Monday, April 29th. Credit Suisse Group cut their target price on Diplomat Pharmacy from $8.00 to $6.00 and set a “neutral” rating on the stock in a research note on Monday, April 29th. ValuEngine raised Diplomat Pharmacy from a “hold” rating to a “buy” rating in a research note on Friday, May 10th. Wells Fargo & Co cut their target price on Diplomat Pharmacy from $16.00 to $6.00 and set a “market perform” rating on the stock in a research note on Tuesday, March 19th. Finally, Barclays reissued an “overweight” rating and issued a $8.00 target price (down from $18.00) on shares of Diplomat Pharmacy in a research note on Monday, February 25th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and two have issued a buy rating to the company. Diplomat Pharmacy currently has a consensus rating of “Hold” and a consensus price target of $10.25.

Institutional investors have recently added to or reduced their stakes in the stock. FMR LLC boosted its position in shares of Diplomat Pharmacy by 61.8% during the fourth quarter. FMR LLC now owns 1,189,312 shares of the company’s stock valued at $16,008,000 after buying an additional 454,112 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Diplomat Pharmacy by 21.8% during the fourth quarter. Rhumbline Advisers now owns 161,436 shares of the company’s stock valued at $2,173,000 after buying an additional 28,901 shares during the last quarter. BDO Wealth Advisors LLC purchased a new stake in shares of Diplomat Pharmacy during the fourth quarter valued at $27,000. Arizona State Retirement System boosted its position in shares of Diplomat Pharmacy by 6.3% during the fourth quarter. Arizona State Retirement System now owns 87,165 shares of the company’s stock valued at $1,173,000 after buying an additional 5,133 shares during the last quarter. Finally, Citigroup Inc. boosted its position in shares of Diplomat Pharmacy by 19.5% during the fourth quarter. Citigroup Inc. now owns 90,102 shares of the company’s stock valued at $1,213,000 after buying an additional 14,709 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

NYSE DPLO opened at $4.58 on Friday. Diplomat Pharmacy has a 12 month low of $4.34 and a 12 month high of $28.74. The firm has a market capitalization of $359.37 million, a PE ratio of 22.90 and a beta of 0.82. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.66 and a current ratio of 1.00.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Featured Article: Call Option Volume

Get a free copy of the Zacks research report on Diplomat Pharmacy (DPLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.